Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, shared a post on X:
“Oral myeloma: sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study.
Important study – stopping therapy with sustained MRD -ve for 3 years is possible for patients (we do that in UAMS Myeloma Center).
23% converted to MRD +ve and only 8% actually had progression after 3 years of follow-up.
We should all do finite therapy especially for standard risk myeloma.”
More posts featuring Samer Al Hadidi.
